Pasithea Therapeutics (KTTA) vs Palatin Technologies (PTN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Palatin Technologies (PTN) has outperformed Pasithea Therapeutics (KTTA) over the past year, gaining 25.3% versus a loss of 40.8%. Over five years, PTN leads with a -98.3% price change compared with -99.2% for KTTA. Pasithea Therapeutics is the larger company by market cap ($15.6 million vs $15.3 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | KTTA | PTN |
|---|---|---|
| Share price | $0.4675 | $8.60 |
| Market cap | $15.62M | $15.32M |
| 1-day change | +6.03% | -4.55% |
| YTD return | -63.76% | -41.42% |
| 1-year return | -40.82% | +25.31% |
| 5-year return | -99.22% | -98.32% |
| EPS (TTM) | $-1.67 | $-2.96 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $2.06 | $31.00 |
| 52-week low | $0.281 | $5.61 |
| Distance from 52-week high | -77.31% | -72.26% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +541.71% | +522.09% |
| Average volume | 226.32K | 63.25K |
| Shares outstanding | 33.41M | 1.78M |
| Employees | 5 | 25 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PTN has outperformed KTTA by 66.1 percentage points over the past year.
About Pasithea Therapeutics
KTTA stock →Pasithea Therapeutics Corp., a clinical-stage biotechnology company, focuses on the discovery, research, and development of treatments for central nervous system (CNS) disorders, RASopathies, and cancers. Its lead product candidate is PAS-004, a next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor to treat a range of RASopathies, including neurofibromatosis type 1 (NF1); MAPK pathway-driven tumors, such as BRAFv600 and BRAF fusion tumor; and ETS2 driven diseases, including inflammatory bowel disease (IBD), primary sclerosing cholangitis, and ankylosing spondylitis.
Health Care · Biotechnology: Pharmaceutical Preparations · 5 employees
About Palatin Technologies
PTN stock →Palatin Technologies, Inc., a biopharmaceutical company, develops first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system in the United States. It is developing oral small molecule PL7737 agonist in preclinical studies; long-acting peptide MC4R agonists; and Bremelanotide co-administration with Tirzepatide to treat obesity completed Phase 2 clinical trial; completed a phase 2 of diabetic nephropathy It also provides pl9643 for dry eye disease; and oral PL8177 for inflammatory bowel diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 25 employees
KTTA vs PTN FAQ
Which is bigger, Pasithea Therapeutics or Palatin Technologies?
Pasithea Therapeutics (KTTA) is larger, with a market capitalization of $15.62M compared with $15.32M for Palatin Technologies (PTN).
Which stock has performed better over the past year, KTTA or PTN?
PTN returned +25.31% over the past 12 months, compared with -40.82% for KTTA (price return, excluding dividends). Past performance does not predict future results.
Are Pasithea Therapeutics and Palatin Technologies in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.